FORTHEM Alliance Unveils Strategy and Goals for Next 4 Years miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
German Research Foundation (DFG) approves funding for world-class science in the field of materials science / Renewal of the Collaborative Research Ce..
Embryo Screening: The Story Of Germany's First PGD Baby worldcrunch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from worldcrunch.com Daily Mail and Mail on Sunday newspapers.
KU Leuven enters international licence agreement on cancer therapy
These updates are republished press releases and communications from members of the Science|Business Network
TEAD inhibition holds great promise as a therapeutic approach as the Hippo pathway is genetically altered in up to 10% of cancers. In mesothelioma, an aggressive and untreatable cancer often caused by asbestos exposure, 60 to 70% of patients have mutations in the Hippo pathway leading to striking sensitivity to TEAD-inhibitors.
SpringWorks Expects to Nominate a Development Candidate and Commence IND-Enabling Studies in 2022
LEUVEN, Belgium, May 6, 2021 – KU Leuven, CD3 and VIB today announced that they have entered into an exclusive worldwide license agreement with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) for a portfolio of novel small molecule inhibitors of the Transcriptional Enhanced Associate Domain (TEAD) family of transcription factors, designed for the potential treatme